Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 14,058 Shares

Posted by Casey Walker on Apr 16th, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 14,058 shares of the firm’s stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $26.54, for a total transaction of $373,099.32. Following the transaction, the insider directly owned 76,140 shares in the company, valued at approximately $2,020,755.60. The trade was a 15.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total transaction of $175,585.68.
On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.38, for a total transaction of $59,414.60.
On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total transaction of $173,744.76.
On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.26, for a total transaction of $369,163.08.
On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $26.84, for a total transaction of $58,269.64.
On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.59, for a total transaction of $11,505.03.
On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total transaction of $184,057.51.
On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.44, for a total transaction of $385,669.20.
On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $30.21, for a total transaction of $65,585.91.
On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.10, for a total transaction of $13,353.60.

Mineralys Therapeutics Trading Up 11.3%

Mineralys Therapeutics stock opened at $30.42 on Thursday. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -12.84 and a beta of 0.69. The company’s 50-day moving average price is $27.26 and its two-hundred day moving average price is $34.36. Mineralys Therapeutics, Inc. has a 52 week low of $12.59 and a 52 week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. Research analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MLYS. Jefferies Financial Group reaffirmed a “hold” rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Friday, March 13th. HC Wainwright set a $56.00 price objective on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen raised shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Bank of America lifted their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Stifel Nicolaus lifted their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.14.

Check Out Our Latest Stock Analysis on MLYS

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently made changes to their positions in MLYS. AQR Capital Management LLC acquired a new position in shares of Mineralys Therapeutics in the 1st quarter worth approximately $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after acquiring an additional 702 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after acquiring an additional 186,480 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Mineralys Therapeutics in the first quarter worth approximately $757,000. Finally, Creative Planning purchased a new position in shares of Mineralys Therapeutics in the second quarter worth approximately $336,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.